NASDAQ:GLPG
Galapagos NV Stock News
$28.76
+0.130 (+0.454%)
At Close: Apr 26, 2024
After Plunging -7.94% in 4 Weeks, Here's Why the Trend Might Reverse for Galapagos (GLPG)
10:36am, Wednesday, 03'rd Apr 2024
The heavy selling pressure might have exhausted for Galapagos (GLPG) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts
Down -14.35% in 4 Weeks, Here's Why Galapagos NV (GLPG) Looks Ripe for a Turnaround
10:36am, Monday, 18'th Mar 2024
Galapagos NV (GLPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estima
Buy These 4 Low-Beta Stocks to Counter Market Volatility
09:46am, Friday, 15'th Dec 2023
It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Virco Mfg (VIRC), Galapagos NV (GLPG), Axonics (AXNX) and Stride (LRN) are well-poised to gain.
New Strong Buy Stocks for December 13th
07:32am, Wednesday, 13'th Dec 2023
TZOO, GLPG, BBVA, TW and STNE have been added to the Zacks Rank #1 (Strong Buy) List on December 13, 2023.
Galapagos NV (GLPG) Q3 2023 Earnings Call Transcript
09:14am, Sunday, 05'th Nov 2023
Galapagos NV (NASDAQ:GLPG ) Q3 2023 Earnings Conference Call November 3, 2023 8:00 AM ET Company Participants Sofie Van Gijsel - Head, IR Paul Stoffels - CEO, Chairman, Interim Head, R&D Thad Huston -
Galapagos NV (GLPG) Q2 2023 Earnings Call Transcript
04:30pm, Friday, 04'th Aug 2023
Galapagos NV (NASDAQ:GLPG ) Q2 2023 Results Conference Call August 4, 2023 8:00 AM ET Company Participants Sofie Van Gijsel - Head, IR Paul Stoffels - CEO, Chairman, Interim Head, R&D Thad Huston - CF
Galapagos Stands Strong On Jyseleca Positive Clinical Data
01:59am, Saturday, 06'th May 2023
Galapagos' focuses on immunology and oncology, with its flagship Jyseleca being used to treat rheumatoid arthritis and ulcerative colitis in Europe and Japan. The company is also developing CAR-T ther
Galapagos NV (GLPG) Q4 2022 Earnings Call Transcript
10:35am, Friday, 24'th Feb 2023
Galapagos NV (NASDAQ:GLPG ) Q4 2022 Earnings Conference Call February 24, 2023 8:00 AM ET Company Participants Sofie Van Gijsel - Senior Director of Investor Relations Paul Stoffels - Chief Executive
Galapagos: Crohn's Disease Trial Failure, Still Maintaining A Buy Rating
07:07am, Saturday, 11'th Feb 2023
On February 8th, 2023, Galapagos announced disappointing results of their phase 3 DIVERSITY Crohn's disease study; the company is no longer planning to file an MAA. Galapagos stock fell 8%, and the st
Galapagos shares down after announcing clinical-trial miss for Crohn's disease
08:35am, Thursday, 09'th Feb 2023
U.S.-listed shares of Galapagos GLPG, +0.41% were down 8.9% in premarket trading on Thursday, the day after the company said an experimental treatment for Crohn's disease missed the primary endpoints
Galapagos to present at 41th Annual J.P. Morgan Healthcare Conference
04:01pm, Tuesday, 03'rd Jan 2023
Mechelen, Belgium; 3 January 202 3 , 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) will participate in the 4 1t h Annual J.P. Morgan Healthcare Conference on January 9 -1 2 , 202 3 .
Galapagos: Slow Transformation, But Led By An Expert
12:54am, Saturday, 31'st Dec 2022
GLPG is setting to transform its business after a slew of failures. The new CEO is a global expert at this, and I don't see him failing.
3 Beaten-Down Drug Stocks Poised for a Turnaround in 2023
11:36am, Wednesday, 28'th Dec 2022
Here we present three drug and biotech stocks, VIR, GLPG and PCRX, which took a beating in 2022 but have upside potential for 2023, despite an uncertain macro environment.
Does Galapagos NV (GLPG) Have the Potential to Rally 34% as Wall Street Analysts Expect?
02:55pm, Friday, 16'th Dec 2022 Zacks Investment Research
The average of price targets set by Wall Street analysts indicates a potential upside of 34.4% in Galapagos NV (GLPG). While the effectiveness of this highly sought-after metric is questionable, the p
Galapagos and CellPoint presented encouraging initial data at ASH 2022 for GLPG5101, a CD19 CAR-T candidate manufactured at point-of-care
06:00am, Tuesday, 13'th Dec 2022 GlobeNewswire Inc.
Mechelen, Belgium; 13 December 2022, 7.00 CET; Galapagos NV (Euronext & NASDAQ: GLPG) and CellPoint (a Galapagos company) today presented encouraging initial data from the ongoing ATALANTA-1 Phase 1/2